Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biohit is working on a new market launch and FDA approval

BIOBVAnalyst Comment10.10.2024, 07.17
Antti SiltanenAnalyst
Discuss

Translation: Original published in Finnish on 10/10/2024 at 7:07 am EEST.

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth. The company said it is working on a major market launch that, if successful, could bring sales from mid-2025. The FDA approval project is also proceeding according to plan and the company is seeking a marketing authorization in the United States in 2026. 

Growth paved by FDA marketing authorization project and potential new market launch next year

Biohit said the FDA project is progressing according to plan, with the aim of obtaining marketing authorization in 2026. We understand that the project is an application for marketing authorization of Gastropanel® and that obtaining it would provide Biohit with access to a significant US market. What makes the market attractive is its large size, uniform regulation and high achievable prices. Towards the end of Biohit's 2024-2028 strategy period, we expect the US to play a moderately large role in achieving its goals. The company also announced a major market launch that, if successful, would bring sales from the middle of next year. No further details are available at this time, but the company has previously mentioned South America as a potential region. According to the company, positive signals are also coming from South Korea, where the long-term work is beginning to show in sales.

Tough regulatory environment for the entire industry in Europe

Biohit also reported that it continued its efforts to expand its product portfolio. In addition to product development, this requires regulatory approval of products in different market areas. In Europe, in vitro diagnostic products must comply with the In Vitro Diagnostic Medical Devices Regulation (IVDR). Compliance applies to both new and old products. This is a major challenge for the whole industry and, we believe, also for Biohit. The company says it has responded to this regulatory challenge with new R&D investments, an extensive network of collaborations and prioritization. We estimate that the slow regulatory environment has already delayed the launch of Biohit's new products and added costs. However, we do not expect regulatory challenges to be a significant headwind for Biohit. The regulatory challenges are also the same for all operators in Europe, so the friction is affecting the market as a whole.

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures08.08.2024

202324e25e
Revenue13.115.117.4
growth-%19.2 %15.9 %15.3 %
EBIT (adj.)1.82.02.3
EBIT-% (adj.)13.4 %13.3 %12.9 %
EPS (adj.)0.120.130.13
Dividend0.000.000.00
Dividend %
P/E (adj.)16.616.415.6
EV/EBITDA11.710.28.7

Forum discussions

Here is a company report on Biohit from Antti. Biohit’s share price has fallen significantly following the H1 report, even though there has ...
11/4/2026, 6:25 AM
by Sijoittaja-alokas
5
That’s certainly true. But since there’s hardly any other information available, it raises doubts about where the share is heading—already in...
10/22/2026, 12:29 PM
by Ehemot
1
Yes, there is, roughly a good 30% of the total number of shares. One of that size is most likely preparing for inorganic growth; after all, ...
10/21/2026, 7:52 AM
by Puutaheinää
2
Isn’t there some vague, really massive share issue authorization “in the pipeline” that at least no retail investor knows what it’s going to...
10/21/2026, 7:44 AM
by Ehemot
2
Biohit has dropped rapidly to roughly the level it was at 3 years ago. I find this quite strange considering how the company’s numbers are developing...
10/21/2026, 7:37 AM
by Puutaheinää
6
And here are Antti’s latest comments on Biohit Biohit published the CEO’s Q3 blog post on Wednesday, which provided a qualitative review of ...
10/15/2026, 5:12 AM
by Sijoittaja-alokas
4
A new CEO blog post was published by Biohit today: Biohit Biohit - IR-blogi Biohit Oyj on vuonna 1988 perustettu globaaleilla markkinoilla toimiva...
10/14/2026, 12:46 PM
by Antti Siltanen
9